According to recent filings submitted to the U.S. Securities and Exchange Commission, Christopher Patusky, a member of the board of directors at United Therapeutics Corp., has finalized a transaction involving the sale of 2,910 shares of common stock. These shares were sold at a price point of $569.00 per share, resulting in a total sale value of $1,655,790.
The liquidation process was preceded by the exercise of stock options. Through this exercise, Patusky acquired 2,910 shares at an individual exercise price of $101.80 per share, which represented a total cost of $296,238. It is important to note that both the acquisition of these shares via option exercise and the subsequent sale were conducted in accordance with a Rule 10b5-1 trading plan, a mechanism Patusky put in place on December 18, 2025.
Following these specific transactions, Patusky's holdings in United Therapeutics have been adjusted. He now directly holds 1,490 shares of the company's common stock. In addition to his direct ownership, he maintains an indirect holding of 1,100 shares through a trust.
The timing of this insider activity coincides with a period of high valuation for United Therapeutics. The stock has experienced a remarkable 93% increase over the past year and is currently trading near its 52-week high of $607.89. Despite recent price strength, analysis from InvestingPro suggests that the stock may currently be overvalued when measured against its estimated Fair Value.
While this insider selling has occurred, United Therapeutics continues to advance its clinical and regulatory roadmap. The corporation is scheduled to present 11 different data presentations at the Annual Meeting of the International Society for Heart and Lung Transplantation. These presentations are set to feature interim analyses from the ARTISAN and PHINDER studies, which examine treatments related to arterial hypertension and pulmonary hypertension.
In terms of regulatory milestones, the company's investigational liver support device, miroliverELAP, has been granted Regenerative Medicine Advanced Therapy designation by the FDA. This designation is a notable step for the device, which is intended to provide temporary support for patients suffering from acute liver failure.
Market analysts have also recently updated their outlooks on the company. Raymond James initiated coverage with an Outperform rating and a price target of $700, citing optimistic sales expectations for Tyvaso in the context of idiopathic pulmonary fibrosis. H.C. Wainwright has maintained a Buy rating while raising its price target to $660, pointing toward promising data from the TETON-1 trial. Furthermore, BofA Securities increased its price target to $626 following positive results from the Phase 3 TETON-1 trial, which supports the efficacy of Tyvaso for treating idiopathic pulmonary fibrosis.